Annovis Bio (ANVS)
(Delayed Data from NYSE)
$7.69 USD
-0.56 (-6.79%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $7.68 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Annovis Bio, Inc. [ANVS]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Buntanetap Shows Promise in Parkinson''s Disease; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Buntanetap Shows Signs of Impact in Pivotal Alzheimer''s Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Parkinson''s Disease Data Next Month; 1Q24 Financials; Lowering PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Buntanetap Shows Encouraging Evidence of Efficacy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Readout Imminent; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Buntanetap Alzheimer''s Disease Pivotal Trial Data Next Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Buntanetap Pivotal Alzheimer''s Disease Trial Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Parkinson''s Disease Clinical Program Timeline Refined; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Alzheimer''s Disease Pivotal Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ANVS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Capital Raise; Pivotal Trials Maturing; 3Q23 Financials; Lowering PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Review Confirms Sufficient Alzheimer''s Disease Study Powering; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
New Provisional Patent Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Buntanetap Phase 3 Trial Enrollment Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results; New Patent Issuance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Recruitment Update and Interim Analysis Appear Favorable; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Additional Sites Authorized For Buntanetap Pivotal Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
Buntanetap Parkinson''s Trial Interim Analysis Next Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Annovis Bio, Inc.
Industry: Medical - Biomedical and Genetics
FDA Authorizes Buntanetap Phase 2/3 Alzheimer''s Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R